On September 21, 2022, Guard Therapeutics hosted a Capital Markets Day at Erik Penser Bank in Stockholm to provide an update on the company's development projects and the clinical strategy for the investigational drug RMC-035 (ROSgard). The presentations were recorded and are now available on the company's website.
The Capital Markets Day began with a presentation by Professor Alexander Zarbock, M.D. from the University Hospital of Münster, a global expert and key opinion leader in the field of acute kidney injury (AKI). He provided an overall summary of the field and specifically commented on the large medical need and lack of treatment options for patients developing AKI following cardiac surgery.
Representatives from Guard Therapeutics then presented the overall scientific background of RMC-035, the primary clinical development program in cardiac surgery associated AKI and also the strategy for a second clinical program in kidney transplantation. The day ended with CEO Tobias Agervald summarizing current and future market considerations and pricing, followed by an open question and answer session.
All presentations from the Capital Markets Day are now available on Guard Therapeutics' website Reports and presentations - Guard Therapeutics